LGI1-Antibody Encephalitis clinical trials at UCSF
1 research study open to eligible people
LGI1-antibody encephalitis is a brain condition where the immune system attacks healthy brain cells. UCSF is running studies to see how well a drug called Satralizumab works for patients with this condition. These studies also check the drug's safety and how it moves through the body.
Showing trials for
Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.
San Francisco, California and other locations
Last updated: